U.S. Supercomputing Needs More Money

STOCKHOLM--The Nobel Foundation plans to sell stock in a new firm being formed to preserve the value of the annual prizes it awards.. . . This year's prizes.. . will each be worth $340,000... . Shrewd investments in the past decade. . . have reversed years of declining value for the prizes, and have raised the foundation's assets to near the real value of the original estate in 1900. --From THE SCIENTIST October 5, 1987, p.4. Lend an ear to hear the story of my galloping success. I was onc

| 4 min read

Register for free to listen to this article
Listen with Speechify
0:00
4:00
Share

--From THE SCIENTIST October 5, 1987, p.4.

Lend an ear to hear the story of my galloping success.
I was once a Wall Street broker(inside, trader, more or less)
But my future brightened quickly
Fast enough to lead to shock
When the staid Nobel Foundation
Said that it would issue stock

I began to buy it slowly
Craftily, with guile and care
Till it soon became apparent
I controlled the lion's share

Owning fifty-one percent
Makes one the boss-as we all know

So I called a public meeting
And named myself the CEO.

The CEO is there to manage
Any problems that arise
And the main one I adressed was-
Who should get the Nobel Prize
One who gets it must be brilliant
Blessed with competence and
In a flash it came upon me
If that is what it takes-I fit!

First I took the one in Physics But my ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies